alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 676–700 of 1,335 studies published 2020 (page 28 of 54) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Deep Convolutional Neural Networks and Transfer Learning for Measuring Cognitive Impairment Using Eye-Tracking in a Distributed Tablet-Based Environment

✓ Peer-reviewed alzhub usefulness score 48 out of 100. IEEE transactions on bio-medical engineering 2020-12-21

This work demonstrates a mobile version of VisMET capable of estimating the presence of cognitive impairment. 1 key finding →

Participants: 250 Evidence: low

Full summary, score breakdown and related studies → Original source

Identification of early pericyte loss and vascular amyloidosis in Alzheimer's disease retina

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Acta neuropathologica 2020-02-10

Pericyte loss and deficient vascular platelet-derived growth factor receptor-β (PDGFRβ) signaling are prominent features of the blood-brain barrier breakdown described in Alzheimer's disease (AD) that can predict cognitive decline yet have never been studied in the retina. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source

Gut mycobiome and its interaction with diet, gut bacteria and alzheimer's disease markers in subjects with mild cognitive impairment: A pilot study

✓ Peer-reviewed alzhub usefulness score 48 out of 100. EBioMedicine 2020-08-30

Compared to CN counterparts, patients with MCI have higher proportion of families Sclerotiniaceae, Phaffomyceteceae, Trichocomaceae, Cystofilobasidiaceae, Togniniaceae and genera Botrytis, Kazachstania, Phaeoacremonium and Cladosporium and lower abundance of Meyerozyma. 2 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source

Increasing Complexity of New Nursing Home Residents in Ontario, Canada: A Serial Cross-Sectional Study

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of the American Geriatrics Society 2020-03-02

Admission trends show that new residents were older and had greater multimorbidity and limitations in physical functioning over time. 1 key finding →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source

Evolution of neuroinflammation across the lifespan of individuals with Down syndrome

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Brain : a journal of neurology 2020-12-01

Epidemiological and experimental studies suggest that a disease-aggravating neuroinflammatory process is present at preclinical stages of Alzheimer's disease. 4 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neurobiology of aging 2020-07-25

Cerebrospinal fluid (CSF) neurofilament light (NfL) concentration has reproducibly been shown to reflect neurodegeneration in brain disorders, including Alzheimer's disease (AD). 3 key findings →

Participants: 227 Evidence: low

Full summary, score breakdown and related studies → Original source

Deep Learning-Based Screening Test for Cognitive Impairment Using Basic Blood Test Data for Health Examination

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Frontiers in neurology 2020-12-14

There were significant positive correlations between the predicted MMSE scores and ground truth scores in the Patient and Healthy groups (r = 0.66, p < 0.001). 5 key findings →

Participants: 202 Evidence: low

Full summary, score breakdown and related studies → Original source

AD-Related CSF Biomarkers Across Distinct Levels of Cognitive Impairment: Correlations With Global Cognitive State

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of geriatric psychiatry and neurology 2020-08-06

In the total sample, T-tau and Aβ42/p-tau correlated with the total CAMCOG (P < .01); all biomarkers correlated with memory (P < .001); T-tau correlated with language (P < .01). 3 key findings →

Participants: 51 Evidence: low

Full summary, score breakdown and related studies → Original source

The Functionality, Evidence, and Privacy Issues Around Smartphone Apps for the Top Neuropsychiatric Conditions

✓ Peer-reviewed alzhub usefulness score 48 out of 100. The Journal of neuropsychiatry and clinical neurosciences 2020-07-16

Eighty-three apps were reviewed (stroke, N=8; migraine, N=25; Alzheimer's disease and dementia, N=8; depression, N=7; anxiety, N=14; apps targeting depression and anxiety, N=21). 4 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source

Polygenic risk for Alzheimer's disease shapes hippocampal scene-selectivity

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2020-01-02

Preclinical models of Alzheimer's disease (AD) suggest APOE modulates brain function in structures vulnerable to AD pathophysiology. 5 key findings →

Participants: 608 Evidence: low

Full summary, score breakdown and related studies → Original source

Shared Causal Paths underlying Alzheimer's dementia and Type 2 Diabetes

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Scientific reports 2020-03-05

Although Alzheimer's disease (AD) is a central nervous system disease and type 2 diabetes MELLITUS (T2DM) is a metabolic disorder, an increasing number of genetic epidemiological studies show clear link between AD and T2DM. 5 key findings →

Participants: 448 Evidence: low

Full summary, score breakdown and related studies → Original source

Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study

✓ Peer-reviewed alzhub usefulness score 48 out of 100. European journal of nuclear medicine and molecular imaging 2020-06-29

In the 98 participants with long follow-up, Centiloid = 26 provided the highest overall predictive value = 87% (NPV = 85%, PPV = 88%). 5 key findings →

Participants: 37 Evidence: low

Full summary, score breakdown and related studies → Original source

[Dementia prevention and primary care: Estimation of the target population]

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Fortschritte der Neurologie-Psychiatrie 2020-09-02

In a sample of 2,398,405 patients receiving primary care, the target population relevant for dementia prevention measures in 2018 consisted of 191,883 patients with hypertension, 23,308 with obesity, 5,059 with hearing loss, 120,200 with diabetes and 43,233 with depression. 5 key findings →

Participants: 51 Evidence: low

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed